Johnson & Johnson Statement on Alabama Opioid Settlement Agreement

NEW BRUNSWICK, NJ, April 19, 2022 - Johnson & Johnson and its U.S.-based Janssen Pharmaceutical Companies (collectively, the “Company”) today announced a settlement agreement with the State of Alabama and its participating subdivisions resolving current and future opioid-related claims against the Company. With this agreement, the Company is removed from filed cases in the state.The $77 million settlement with Alabama is consistent with the framework of the recently finalized nationwide opioid settlement agreement. This settlement is not an admission of any liability or wrongdoing and the Company will continue to defend against any litigation that the final agreement does not resolve.The Company’s actions relating to the marketing and promotion of important prescription opioid medications were appropriate and responsible. DURAGESIC®, NUCYNTA® and NUCYNTA® ER accounted for less than one percent of total opioid prescriptions in Alabama and the U.S. since launch. The Company no longer sells prescription opioid medications in the United States as part of its ongoing efforts to focus on transformational innovation and serving unmet patient needs. For more information, visit www.FactsAboutOurPrescriptionOpioids.com.Cautions Concerning Forward-Looking StatementsThis statement contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding settlement agreements to resolve opioid-related claims and litigation. The rea...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news